【摘要】 目的比较支气管动脉灌注(BAI)联合全身静脉化疗与单纯全身静脉化疗治疗非小细胞肺癌(NSCLC)的疗效和毒副反应。方法60例ⅢA～Ⅳ期NSCLC随机分为BAI联合全身静脉化疗组(治疗组)30例和单独全身静脉化疗组(对照组)30例。结果治疗组有效率66.7%,对照组有效率40.0%,治疗组疗效明显优于对照组(P<0.05);中位缓解期及1年生存期无显著差别(P>0.05)。骨髓抑制发生率治疗组和对照组分别为80.70%(24/30)和96.7%(29/30),差异有显著性(P<0.05);消化道反应发生率分别为73.3%(22/30)和93.3%(28/30),差异有显著性(P<0.05)。结论吉西他宾联合顺铂方案通过支气管动脉灌注及全身静脉化疗优于单纯全身化疗,具有较好的近期疗效,且毒副反应轻,是治疗中晚期NSCLC的较好方案之一。更多还原

【Abstract】 Objective To compare the efficacy,side-effect and toxicity between bronchial artery infusion(BAI) of gemcitabine plus cisplatin combining systemic chemotherapy and stemic chemotherapy only for advanced non-small cell lung cancer(NSCLC).Methods The 60 patients with NSCLC in stage ⅢA～Ⅳ were divided randomly into treatment and control group,30 atients per group.The patients in the treatment group were administered with BAI chemotherapy plus systemic chemotherapy and in the control group were treated with systemic chemotherapy only.Results The overall response rate was 66.7% in the treatment group and 40.0% in the control group.The treatment group is more advantageous over the control group(P<0.05).There was no significant difference between the two groups in median progressive time and 1-year survival time(P>0.05).Myelosuppression occurred in 80.70%(treatment group) and 96.7 %(control group);gastrointestinal toxicities was 73.3 % and 93.3 % respectively.The side effects were milder in the treatment group(P<0.05).Conclusions This study demonstrated that bronchial artery infusion(BAI) chemotherapy plus systemic chemotherapy is more advantageous over systemic chemotherapy as gemcitabine plus cisplatin was administered in advanced non-small cell lung cancer(NSCLC) in higher response rate,less toxicities.Bronchial artery infusion(BAI) chemotherapy plus systemic chemotherapy was recommended as a better means for metaphase and advanced NSCLC.更多还原